Drug Review Times Not Shortened Much by Single Expedited Review Designation

Expedited programs usually shorten a US Food and Drug Administration new drug application assessment, but on average, maybe not as much as their reputation would suggest.

A Government Accountability Office (GAO) analysis found that expedited assessment programs generally are significant variables affecting assessment times, but less so than perhaps stakeholders might expect.